COMMUNIQUÉS West-GlobeNewswire

Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
20/08/2026
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to [...]
Flyte Surpasses 10,000 Consumer Accounts as WebApp Growth Accelerates
20/08/2026
New Account Creation Increased 170% During the First 17 Days of August Compared to the Same Period in July Flyte Has Added More Accounts Since July 1 Than During the Entire First Half of 2026 Growing First-Party [...]
Herantis Pharma releases 1H 2026 report today
20/08/2026
Espoo, Finland, August 20, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the Company’s 1H 2026 [...]
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
20/08/2026
Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical proof-of- [...]
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
20/08/2026
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe and well tolerated [...]
George Medicines announces GMRx2 presentations at the European Society of Cardiology Congress 2026
20/08/2026
London, UK, Boston, MA, 20 August 2026 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today announced that data on GMRx2, its single [...]
Grey Matters Announces CAD $800K of Private Placement Equity Financing and Convertible Debentures
20/08/2026
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “ Company” or “ Grey Matters ”) (CSE [...]
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
20/08/2026
Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest NASHVILLE, Tenn., Aug. 20, [...]
Tilray Strengthens Global Medical Cannabis Leadership with Major Production Increase to Meet International Demand
20/08/2026
Expanded cultivation in Quebec and Portugal strengthens Tilray’s global cannabis platform, increasing total annual production capacity to approximately 275 metric tonnes to support accelerating international medical [...]
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
20/08/2026
Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders Appointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to [...]
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
20/08/2026
Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to [...]
Why Work With Transcom: Disability Inclusion Recognized for a Second Year
20/08/2026
Transcom is recognized for the second consecutive year as a World’s Top Disability Inclusive Business on the Disability Index®, a leading global benchmark for workplace disability inclusion. In 2026, Transcom operations [...]
Verano Enters Cannabis Beverage Category with Debut of Easy Landings, Company’s First National Beverage Brand Featuring Four Delicious Flavors and All-Natural Ingredients
20/08/2026
Leveraging consumer trends favoring alternative and macrodose cannabis products, THC drinks and alcohol-free options, Easy Landings 100 mg single serve beverages feature four delicious flavors with all natural, vegan [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
20/08/2026
NANJING, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinical study evaluating [...]
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
20/08/2026
Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in [...]
BioPorto announces Interim Results for the Second Quarter and First half of 2026
20/08/2026
August 20, 2026 Announcement no. 14 BioPorto announces Interim Results for the Second Quarter and First half of 2026 Copenhagen, Denmark, August 20, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or [...]
Vistin Pharma ASA: Second quarter and YTD 2026 financial results
20/08/2026
Oslo, Norway, 20 August 2026 Vistin Pharma ASA (VISTN) today announces its financial results for the second quarter and first half of 2026. Revenue in the second quarter amounted to MNOK 100, compared to MNOK 118 in Q2 [...]
ALK appoints Jacob Glenting as head of Global R&D
20/08/2026
ALK announces the appointment of Jacob Glenting as new Executive Vice President (EVP) and head of Global R&D, effective 1 September 2026. This position has been vacant since February 2026. Jacob Glenting is [...]
Six-month interim report (Q2) 2026 (unaudited)
20/08/2026
ALK delivers 18% organic revenue growth with operating profit (EBIT) up 19% in Q2 ALK sustained strong momentum in Q2, with double-digit growth across all regions driven by sales of tablets and anaphylaxis products. [...]

Pages